Skip to main content
SpringerLink
Log in

In vitro activity of liposomal N4octadecyl-1-β-D-arabinofurano-sylcytosine (NOAC), a new lipophilic derivative of 1-β-D-arabino-furanocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

N4-octadecyl-1-β-D-arabinofuranosylcytosine (NOAC) is a new lipophilic derivative of1-β-D-arabinofuranosylcytosine(ara-C) with potent antitumor activityagainst leukemias and solid tumors. In thisstudy the activity of NOAC against freshlyexplanted clonogenic cells from humantumors was determined and compared withconventional antitumor agents. NOAC wasused in two liposomal preparations, astable lyophilized and a freshly preparedliquid formulation. Both formulationsinhibited tumor colony formation equally ina concentration-dependent fashion in bothshort- (1h) and long-term (21-28 d)exposure experiments. NOAC (100 μM,long-term exposure) had a significantlybetter activity compared to the clinicallyused drugs cisplatin, doxorubicin,5-fluorouracil, gemcitabine, mitomycin Cand etoposide. The comparison of NOAC withara-C in the long-term exposure experimentshowed that ara-C was more effective at 4and 10 μM, whereas at 1 and 100 μMthere was no difference between the twodrugs. NOAC was less toxic in ahematopoietic stem cell assay than ara-Cand doxorubicin by factors ranging from 2.5to 200, indicating that this drug is welltolerated at high doses. The antitumoractivity of NOAC (NSC 685096) was confirmedby the NCI in vitro drug screening programwhere the drug was found to be activeagainst several types of human tumors.Further development of NOAC in phase IIstudies is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schott H, Häussler MP, Schwendener RA: Synthese von 4-Alkylcytosin-nukleosiden und deren cytotstatische Wirkung im L1210 Leukämiemodell der Maus. Liebigs Ann Chem 465–470, 1994

  2. Schwendener RA, Schott H: Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-β-Darabinofuranosylcytosine. Int J Cancer 51: 466–469, 1992

    Google Scholar 

  3. Schwendener RA, Horber DH, Ottiger C, Rentsch KM, Fiebig HH, Schott H: Alkasar, 1-(β-D-arabinofuranosyl)-4-octadecylamino-2(1H)-pyrimidin-one, N4-octa-decyl-ara-C, NOAC. Drugs Future 20: 11–15, 1995

    Google Scholar 

  4. Schwendener RA, Horber DH, Odermatt B, Rentsch KM, Schott H: Oral antitumor activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-β-D-arabinofuranosylcytosine (ara-C). J Cancer Res Clin Oncol 122: 102–108, 1996

    Google Scholar 

  5. Horber DH, Schott H, Schwendener RA: Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-β-Darabinofuranosylcytosine, a lipophilic derivative of 1-β-Darabinofuranosylcytosine. Br J Cancer 71: 957–962, 1995

    Google Scholar 

  6. Horber DH, Schott H, Schwendener RA: Cellular pharmacology of N4-hexadecyl-1-β-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937. Cancer Chemother Pharmacol 36: 483–492, 1995

    Google Scholar 

  7. Horber DH, Von Ballmoos P, Schott H, Schwendener RA: Cell cycle dependent cytotoxicity and induction of apoptosis by N4-hexadecyl-1-β-D-arabinofuranosylcytosine, a new lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br J Cancer 72: 1067–1073, 1995

    Google Scholar 

  8. Koller-Lucae SKM, Schott H, Schwendener RA: Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-β-Darabinofuranosylcytosine, a new anticancer drug. J Pharmacol Exp Ther 282: 1572–1580, 1997

    Google Scholar 

  9. Koller-Lucae SKM, Schott H, Schwendener RA: Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-β-D-arabinofuranosylcytosine (NOAC) in Daudi lymphoma cells. Br J Cancer 80: 1542–1549, 1999

    Google Scholar 

  10. Koller-Lucae SKM, Suter MJF, Rentsch KM, Schott H, Schwendener RA: Metabolism of the new liposomal anticancer drug N4-octadecyl-1-β-D-arabinofuranosylcytosine in mice. Drug Metabolism and Disposition 27: 342–350, 1999

    Google Scholar 

  11. Hanauske AR, Wüster KC, Lehmer A, Rotter M, Schneider P, Kaeser-Frohlich A, Rastetter J, Depenbrock H: Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumors in vitro. Eur J Cancer 31A: 1677–81, 1995

    Google Scholar 

  12. Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR: In vitro activity of aplidine, a new marinederived anti-cancer compound, on freshly explanted clonogenic human tumor cells and haematopoietic precursor cells. Br J Cancer 78: 739–744, 1998

    Google Scholar 

  13. Raymond E, Hanauske A, Faivre S, Izbicka E, Clark G, Rowinsky EK, Von Hoff DD: Effects of prolonged versus shortterm exposure paclitaxel (Taxol) on human tumor colonyforming units. Anticancer-Drugs 8: 379–385, 1997

    Google Scholar 

  14. Depenbrock H, Schmelcher S, Peter R, Keppler BK, Weirich G, Block T, Rastetter J, Hanauske AR: Preclinical activity of trans-indazolium [tetra-chlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumor colony-forming units and haematopoietic progenitor cells. Eur J Cancer 33: 2404–2410, 1997

    Google Scholar 

  15. Hanauske AR, Hanauske U, Von-Hoff DD: Recent improvements in the human tumor cloning assay for sensitivity testing of antineoplastic agents. Eur J Cancer Clin Oncol 23: 603–605, 1987

    Google Scholar 

  16. Hanauske U, Hanauske AR, Marshall MH, Muggia VA, Von-Hoff DD: Biphasic effect of vanadium salts on in vitro tumor colony growth. Int J Cell Cloning 5: 170–178, 1987

    Google Scholar 

  17. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull KD, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, and Boyd M: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Nat Cancer Inst 83: 757–766, 1991

    Google Scholar 

  18. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J Nat Cancer Inst 81: 1088–1092, 1989

    Google Scholar 

  19. Horber DH, Cattaneo-Pangrazzi RMC, von Ballmoos P, Schott H, Ludwig PS, Eriksson S, Fichtner I, Schwendener RA: Cytotoxicity, cell cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-β-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5_β5_)-N4-octadecyl-1-β-D-ara-C. J Cancer Res Clin Oncol 126: 311–319 2000

    Google Scholar 

  20. Schwendener RA, Horber DH, Ottiger C, Schott H: Preclinical properties of N4-hexadecyl-and N4-octadecyl-1-β-Darabinofuranosylcytosine in liposomal preparations. J Liposome Res 5: 27–47, 1995

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Division of Cancer Research, University Hospital, Zürich, Switzerland

    R.A. Schwendener

  2. Division of Hematology and Oncology, Department of Medicine, Technische Universität München, Munich, Germany

    K. Friedl, H. Depenbrock & A.-R. Hanauske

  3. Institute of Organic Chemistry, University of Tübingen, Germany

    H. Schott

Authors
  1. R.A. Schwendener
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Friedl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Depenbrock
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Schott
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A.-R. Hanauske
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwendener, R., Friedl, K., Depenbrock, H. et al. In vitro activity of liposomal N4octadecyl-1-β-D-arabinofurano-sylcytosine (NOAC), a new lipophilic derivative of 1-β-D-arabino-furanocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells. Invest New Drugs 19, 203–210 (2001). https://doi.org/10.1023/A:1010679411001

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010679411001

Search

Navigation